Accruing evidence suggests that ErbB family members may be useful biomarkers of aggressive disease course and potential drug targets in breast cancer, including triple-negative breast cancer (TNBC), which is defined by the biomarkers/drug targets it lacks, including amplification of ErbB family member HER2. This evidence concerns the gene EGFR and triple-negative breast carcinoma.